Retinal vein occlusion

Retinal vein occlusion occurs when circulation of a retinal vein becomes obstructed by an adjacent blood vessel, causing hemorrhages in the retina. Swelling and ischemia (lack of oxygen) of the retina as well as glaucoma are fairly common complications.

Retinal vein occlusionRetinal vein occlusion

The visual symptoms can vary in severity from one person to the next , and are dependent on whether the central retinal vein or a branch retinal vein is involved.


Patients who experience a branch vein occlusion often notice a gradual improvement in their vision as the hemorrhage resolves. Recovery from a central vein occlusion is much less likely since it affects the macula.

This problems appears equally in males and females and is more common after the age of 60.

Symptoms of Retinal vein occlusion

• Sudden onset
• Blurred or missing area of vision (if a branch vein is involved)
• Severe loss of central vision (if a central vein is involved)

Detection and diagnosis of Retinal vein occlusion

Vein occlusion is diagnosed by examining the retina with an ophthalmoscope. Fluorescein angiography may be performed in some cases to study the circulation of the retina and to determine the extent of macular edema or swelling.

Treatment of Retinal vein occlusion

Following a vein occlusion, the primary concern is to treat the secondary complications. If areas of the retina are oxygen-deprived, laser may be used to prevent growth of delicate vessels that could break, bleed or cause glaucoma.

The following are common risk factors for vein occlusion:
• Diabetes
• Hypertension
• Cardiovascular disease

Eylea (aflibercept) intravitreal injections Central Retinal Vein Occlusion

Aflibercept is a pharmaceutical substance of the drug Eylea. This substance inhibits the activity of a group of factors, known as vascular endothelial growth factors (VEGF) . In patients with central retinal artery occlusion, the central retinal artery or a branch of it is blocked.This results in increase levels of vascular agents (VEGF factors), causing increased macular edema, which because of the fluid collection causes opacities on our vision.

How Eylea is administered?

In the case of secondary macular edema from central retinal vein or artery occlusion personalized treatment is applied, which is determined by your doctor. The frequency of injections which is indicated is one (1) per month. In any case, your doctor will decide whether a patient should continue or discontinue therapy with intravitreal injections. The determinant factor is the improvement of the condition or not, which is judged by measurements of both visual acuity, but mainly by optical coherence tomography (OCT).




Success Rates

Retinal detachment
Final restoration → 98,7%!

Μacular hole, final
restoration → 100%!

Epiretinal Membrane → Final Restoration 100%!
Lameral Hole → research in progress, results will be presented soon


Read More

Opthalmology Health Center


Subscribe to our Newsletter, to be notified about new articles and video
I agree with the privacy policy

Contact us

Telephone: +30 210 7212200

Mobile: +30 210 7212201

Address: Vas. Sofias 66, Athens

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.